The natural history of Fanconi anemia is characterized by progressive marrow failure and evolution to acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and by an increased rate of solid tumors (1--4). AML and MDS in this setting are associated with dismal prognosis. Although allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative approach for AML /MDS in FA patient, it has been associated with significant treatment--related mortality (5). Furthermore induction chemotherapy for AML in FA patients is also associated with significant toxicity and prolonged period of aplasia. The use of sequential chemotherapy and HSCT has been described in non FA patients not in remission (6) . We report the outcome of 6 FA patients who received a sequential regimen strategy because of clonal evolution. From August 2006 to December 2011, 6 consecutive patients with FA (Table 1 ) who received sequential chemotherapy and reduced--intensity conditioning before HSCT for clonal evolution in 4 French institutions were reviewed. Five patients had AML (3 high risks and 2 standard risks according to Medical Research Council) and 1 had a high risk MDS according to the International Prognostic Scoring System. The sequential strategy consisted of pre--transplant chemotherapy with fludarabine 30 mg/m²/d 5 days and cytarabine 1gr/m²x2/d 5 days with granulocyte--colony stimulating factor injections (FLAG) followed 3 weeks after by a reduced--intensity conditioning (4 days cyclophosphamide 10 mg/kg (low dose cyclophosphamide because of FA), 4 days fludarabine 30 mg/m², 2 days anti--thymocyte globulin (3.75 mg/kg) and TBI (2 Gy) delivered during chemotherapy induced aplasia. All patients were still in aplasia when they were transplanted. The source of stem cells was cord blood in three patients (2 cord blood units) and in bone marrow for the remaining 3 others. Graft versus host disease prophylaxis consisted in cyclosporine (CSA) plus MMF (except 1 patient who received CSA plus methotrexate). Median age of the patients at HSCT was 20.5 years (5--28). All patients engrafted. Median time to engraftment was 21 days (range 14 to 35) for neutrophils and 29 days for platelets (range 21 to 42). Donor chimerism was complete at day 100 for 5 patients. The sequential regimen was well tolerated. Three patients developed bacteremia (Staphylococcus, Enterobacter, and Candida) at one, three and one months after HSCT, respectively. One patient developed a diarrhea to Campylobacter jejuni one month after HSCT and another patient underwent surgery for chronic maxillary sinusitis 6 months after HSCT. Acute GVHD (1 grade 1 and 1 grade 2) occurred in two patients. Both responded to steroid therapy. Chronic GVHD occurred in two patients (only skin was involved, corresponding to mild cGvHD according to the NIH working group definition 7 ). After a median follow--up of 28 months (5--72), all patients are alive in complete remission from the clonal evolution, with a median 30 months follow--up. Because of the usual very poor outcome of such patients, we believe this study supports the use for such a sequential strategy (FLAG and RIC HSCT) in FA patients with clonal evolution.
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